0
Signin
countryflagUS

18889881171

MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%

Immunovant Inc

Healthcare US IMVT

28.13USD
0.19(0.68%)

Last update at 2024-07-25T16:50:00Z

Day Range

27.3728.50
LowHigh

52 Week Range

18.1645.58
LowHigh

Fundamentals

  • Previous Close 27.94
  • Market Cap4129.23M
  • Volume674241
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-253.36800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.78

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -210.95100M -156.81400M -107.78900M -66.29100M -0.00045M
Minority interest - - - - -
Net income -210.96000M -156.73000M -107.43100M -66.38800M -0.00045M
Selling general administrative 48.02M 54.23M 39.51M 18.15M 2.69M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.19M 0.13M 0.07M 0.02M -
Ebit -198.46900M -156.15900M -107.78900M -65.66600M -0.00045M
Ebitda -198.27600M -156.03300M -107.72400M -65.64500M -0.00045M
Depreciation and amortization 0.19M 0.13M 0.07M 0.02M -
Non operating income net other -0.25300M -0.78100M 0.33M - -
Operating income -198.46900M -156.15900M -107.78900M -65.66600M -0.00045M
Other operating expenses 208.28M 156.03M 108.12M 66.08M 0.00045M
Interest expense 12.48M 0.66M 0.00000M 0.62M 0.00000M
Tax provision 0.00900M -0.08400M -0.35800M 0.10M -
Interest income 7.58M - - 0.62M -
Net interest income 7.58M - 0.00000M -0.62500M -
Extraordinary items - - - - -
Non recurring 10.00M - - - -
Other items - - - - -
Income tax expense 0.00900M -0.08400M -0.35800M 0.10M 0.02M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 208.28M 156.03M 108.12M 66.08M 0.00045M
Cost of revenue - - - - -
Total other income expense net -12.48200M -0.65500M 0.33M -0.62500M -0.15548M
Discontinued operations - - - - -
Net income from continuing ops -210.96000M -156.73000M -107.43100M -66.38800M -28.59942M
Net income applicable to common shares -210.96000M -156.73000M -107.43100M -66.38800M -28.59900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 405.84M 515.56M 412.49M 109.39M 0.41M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 26.92M 6.25M 8.31M 5.46M 0.08M
Total liab 43.34M 45.74M 21.01M 15.32M 0.38M
Total stockholder equity 362.49M 469.82M 391.48M 94.07M 0.02M
Deferred long term liab - - - 0.25M 1.20M
Other current liab 40.77M 24.75M 15.16M 14.13M 0.08M
Common stock 0.01M 0.01M 0.01000M 0.00500M 0.00029M
Capital stock 0.01M 0.01M 0.01000M 0.00500M 0.00029M
Retained earnings -566.34700M -355.38700M -198.65700M -91.22600M -0.00045M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.25M 1.20M
Cash 376.53M 493.82M 400.15M 100.57M 0.33M
Cash and equivalents - - - - -
Total current liabilities 43.30M 44.52M 18.77M 15.32M 0.38M
Current deferred revenue - - - - -
Net debt -375.31200M -491.45300M -396.72900M -100.57100M -0.02500M
Short term debt 1.17M 1.15M 1.18M - 0.30M
Short long term debt - - - - 0.30M
Short long term debt total 1.22M 2.36M 3.42M - 0.30M
Other stockholder equity 927.98M 824.80M 590.42M 185.31M 0.02M
Property plant equipment 0.33M 0.33M 0.20M 0.07M 0.05M
Total current assets 404.33M 512.93M 409.01M 109.08M 0.33M
Long term investments - - - - -
Net tangible assets 362.49M 469.82M 391.48M 94.07M 7.34M
Short term investments - - - - -
Net receivables 0.89M 12.86M 0.55M 3.04M 2.96M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.35M 18.63M 2.43M 1.19M 0.21M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.85M 0.40M -0.29800M -0.01600M -
Additional paid in capital - - - - -
Common stock total equity 0.01M 0.01M 0.01000M 0.00500M 0.00029M
Preferred stock total equity - - - - -
Retained earnings total equity -566.34700M -355.38700M -198.65700M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.25M 0.08M
Deferred long term asset charges - - - - -
Non current assets total 1.50M 2.63M 3.48M 0.31M 0.08M
Capital lease obligations 1.22M 2.36M 3.42M - -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.19700M -0.25400M -0.21000M -0.03100M -
Change to liabilities -1.40000M 25.90M 5.72M 0.97M -0.92800M
Total cashflows from investing activities -0.19700M -0.25400M -0.21000M -0.03100M -0.05200M
Net borrowings - - -3.19000M 37.91M 37.91M
Total cash from financing activities 70.89M 200.13M 383.11M 146.97M 0.33M
Change to operating activities - 10.61M 3.83M 3.83M -0.47400M
Net income -210.96000M -156.73000M -107.43100M -66.38800M -0.00045M
Change in cash -117.28500M 93.67M 299.57M 93.59M 0.33M
Begin period cash flow 493.82M 400.15M 100.57M 6.99M -
End period cash flow 376.53M 493.82M 400.15M 100.57M 0.33M
Total cash from operating activities -188.19300M -106.11200M -83.32700M -53.35700M -28.54700M
Issuance of capital stock 70.50M 0.00000M 319.78M 0.00000M -
Depreciation 0.19M 0.13M 0.07M 0.02M 0.01M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 11.76M -11.63300M -0.51200M -11.63300M -11.63300M
Sale purchase of stock 70.89M 200.00M 385.21M 0.00100M 0.03M
Other cashflows from financing activities 0.39M 200.13M 66.52M 151.97M 0.30M
Change to netincome 32.30M 34.24M 18.54M 6.58M 1.49M
Capital expenditures 0.20M 0.25M 0.21M 0.03M 0.05M
Change receivables 11.76M -11.63300M - - -
Cash flows other operating -20.08600M 1.98M -0.22000M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -117.50500M 93.76M 299.57M - -
Change in working capital -10.85300M 15.14M 4.57M 4.81M 0.00045M
Stock based compensation 32.30M 34.24M 18.82M 6.96M -
Other non cash items 1.13M 1.11M 0.93M 1.24M -
Free cash flow -188.39000M -106.36600M -83.53700M -53.38800M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
IMVT
Immunovant Inc		 0.19 0.68% 28.13 - - - 6.28 -14.1221
NVO
Novo Nordisk A/S		 -2.29 1.74% 129.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.80 2.90% 135.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.67 0.75% 494.48 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 22.92 2.16% 1083.78 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Immunovant Inc

320 West 37th Street, New York, NY, United States, 10018

Key Executives

Name Title Year Born
Dr. Frank M. Torti M.B.A., M.D., MBA Exec. Chairperson of the Board 1979
Dr. Peter Salzmann M.B.A., M.D. CEO & Director 1968
Ms. Eva Renee Barnett M.B.A. Chief Financial Officer 1980
Dr. William L. Macias M.D., Ph.D. Chief Medical Officer 1958
Dr. Julia G. Butchko Ph.D. Chief Devel. & Technology Officer 1971
Dr. Chau Cheng M.B.A., Ph.D. VP of Investor Relations NA
Mr. Mark S. Levine Chief Legal Officer & Corp. Sec. 1973
Ms. Lauren Schrier M.B.A. VP of Marketing NA
Dr. Frank M. Torti M.B.A., M.D. Executive Chairperson of the Board 1979
Dr. Peter Salzmann M.B.A., M.D. CEO & Director 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.